Inhibikase Therapeutics, Inc. Shareholders' Equity
Inhibikase Therapeutics, Inc. (IKT) had Shareholders' Equity of $153.33 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $153.33M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $167.62M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $172.90M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $72.90M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $153.33M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $167.62M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $172.90M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $72.90M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $80.05M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $85.73M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $94.87M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | -$530.59K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $5.10M 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $6.78M 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $10.98M 10-K · filed 2026-03-26 | |
| 2023-09-30 | $15.02M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $19.46M 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $25.28M 10-Q · filed 2024-11-14 | $25.32M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $21.04M 10-K · filed 2025-03-27 | |
| 2022-09-30 | $25.14M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $29.50M 10-Q · filed 2023-11-14 | |
| 2022-03-31 | $34.01M 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $38.42M 10-K · filed 2024-03-27 | |
| 2021-09-30 | $43.16M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $47.05M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $8.04M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $9.78M 10-K · filed 2023-03-31 | |
| 2020-09-30 | -$5.13M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$4.83M 10-Q · filed 2021-11-15 | |
| 2020-03-31 | -$4.70M 10-Q · filed 2021-11-15 | |
| 2019-12-31 | -$4.49M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |